MedTrace Logo

Rituximab in the Treatment of Patients With Bullous Pemphigoid

NCT00286325 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-04-11

Study results available
· View outcomes & findings →

Summary

This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.

Conditions

  • Bullous Pemphigoid

Interventions

DRUG

Rituximab

Infusion of 1000 mg of rituximab on day 0 and day 14

Sponsors & Collaborators

Principal Investigators

  • Russell Hall, III, MD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00286325 on ClinicalTrials.gov